Promising Clinical Outcomes in SR-aGvHD
*Phase I/II clinical data demonstrated high response rates, encouraging long-term survival, and a favorable safety profile with VIRAPLACEL®.
A.High Clinical Response Following VIRAPLACEL® Treatment
VIRAPLACEL® was evaluated in a prospective, open-label, single-arm Phase I/II clinical study of adults with Grade II–IV steroid-refractory acute graft-versus-host disease (SR-aGvHD) following allogeneic hematopoietic stem cell transplantation (HSCT).
Clinical evaluation at 1–2 months demonstrated an overall response in all treated patients, including complete and partial responses in 66% and 34% of patients, respectively.
B.Durable Survival Following VIRAPLACEL® Treatment
Long-term follow-up demonstrated encouraging survival outcomes in adults with steroid-refractory acute graft-versus-host disease (SR-aGvHD) treated with VIRAPLACEL®.
Overall survival was 80% at 1 year, 70% at 2 years, and 60% at 3 years following treatment.
C.Favorable Safety Profile
The safety of VIRAPLACEL® was evaluated throughout the Phase I/II clinical study in adults with SR-aGvHD.
No serious adverse events were reported, and no patients discontinued treatment because of toxicity or insufficient response.